These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 339270)

  • 1. Methods of monitoring adverse reactions to drugs.
    Venulet J
    Prog Drug Res; 1977; 21():231-92. PubMed ID: 339270
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring adverse reactions to drugs: toward a therapeutic audit.
    Wade OL; Beeley L
    Int J Health Serv; 1974; 4(1):109-23. PubMed ID: 4597989
    [No Abstract]   [Full Text] [Related]  

  • 3. Computer analysis of epidemiologic data on effect of drugs on hospital patients.
    Slone D; Gaetano LF; Lipworth L; Shapiro S; Lewis GP; Jick H
    Public Health Rep (1896); 1969 Jan; 84(1):39-52. PubMed ID: 4974707
    [No Abstract]   [Full Text] [Related]  

  • 4. Publicizing of new drugs.
    Grant-Whyte H
    S Afr Med J; 1979 Apr; 55(17):658. PubMed ID: 462287
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 6. The Clinical Information Center. Part II: design and implementation.
    Freiman AH; Walsh DW
    Clin Bull; 1974; 4(3):91-6. PubMed ID: 4442230
    [No Abstract]   [Full Text] [Related]  

  • 7. A drug information-ADR collection network: the French system.
    Dangoumau J; Lagier G; Royer RJ
    Drug Inf J; 1986; 20(3):337-46. PubMed ID: 10317774
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.
    Feinstein AR
    Clin Pharmacol Ther; 1974 Jul; 16(1):110-23. PubMed ID: 4843239
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting adverse reactions.
    Steen J
    Lancet; 1978 Oct; 2(8096):947. PubMed ID: 81965
    [No Abstract]   [Full Text] [Related]  

  • 10. Telecommunication of multinational clinical data.
    Snoddy CS; Hercus VM; Walford GL; Illies AR; Collins MP; Lohmann WW
    Drug Inf J; 1976; 10(2):71-4. PubMed ID: 800994
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of age, sex, kidney function, atopy and number of prescriptions for the occurrence of adverse drug reactions, studied by multivariate statistical methods. Results from the Comprehensive Hospital Drug Monitoring Berne (CHDMB)].
    Hoigné R; Sollberger J; Zoppi M; Müller U; Hess T; Fritschy D; Stocker F; Maibach R
    Schweiz Med Wochenschr; 1984 Dec; 114(49):1854-7. PubMed ID: 6515386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of indomethacin toxicity: the drug information network and its benefits in therapy.
    Bainbridge CV; Ruger JR
    Drug Inf J; 1979; 13(1):35-40. PubMed ID: 10242951
    [No Abstract]   [Full Text] [Related]  

  • 13. [Undesirable drug effects and their monitoring].
    Vanĕcek J; Fink Z
    Zdrav Aktual; 1979; 191():144-53. PubMed ID: 550638
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse-reactions literature: a bibliometric analysis.
    Windsor DA
    Methods Inf Med; 1977 Jan; 16(1):52-4. PubMed ID: 320429
    [No Abstract]   [Full Text] [Related]  

  • 15. New strategies for drug monitoring.
    Meyboom RH
    Br Med J; 1977 Jun; 1(6077):1663. PubMed ID: 871720
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
    Wiholm BE; Westerholm B
    Acta Med Scand Suppl; 1984; 683():107-17. PubMed ID: 6430038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug information: an overview and prospect for the future.
    Ruger JR; Durgin JM
    Drug Intell Clin Pharm; 1978 Apr; 12(4):231-9. PubMed ID: 10307389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse reactions: getting the best from the yellow card system.
    Drug Ther Bull; 1980 Sep; 18(19):75-6. PubMed ID: 7418611
    [No Abstract]   [Full Text] [Related]  

  • 19. [Medical records and ordinator].
    Chevallier J
    Presse Med (1893); 1969 Mar; 77(12):452-4. PubMed ID: 5785079
    [No Abstract]   [Full Text] [Related]  

  • 20. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.